This post was originally published on this site
(Reuters) – Regeneron (NASDAQ:REGN) Pharmaceuticals said on Monday the U.S. Justice Department’s complaint against the company misreporting the average sales price for its macular degeneration drug Eylea is “meritless” and it plans to defend this case in court.
The Justice Department last week had accused Regeneron of manipulating Medicare’s drug-pricing process by inflating the average sales price for its Eylea drug.
